Progress in development of group A Streptococcus vaccines

Current Pharmaceutical Biotechnology

Volumn 14, Issue 11, 2013, Pages 947-950

  Song, Yingli ^a   Zhang, Xiaolan ^a   Lu, Chunmei ^a   Zhang, Fengmin ^a   Zhu, Hui ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arginine deiminase; Group A carbohydrate; Group A Streptococcus; M protein; ScpA; Shr; SpyCEP; SsE; Streptococcal fibronectin binding proteins; Streptococcal pyrogenic exotoxins; Trigger factor; Vaccine

Indexed keywords

ARGININE DEIMINASE; FIBRONECTIN BINDING PROTEIN; M PROTEIN; PROTEIN G; STREPTOCOCCUS VACCINE; STREPTOLYSIN O; TOXIC SHOCK SYNDROME TOXIN 1; VIRULENCE FACTOR;

AUTOIMMUNE DISEASE; CROSS REACTION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNE EVASION; IMMUNIZATION; NECROTIZING FASCIITIS; NONHUMAN; PHAGOCYTOSIS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATIC HEART DISEASE; SEROTYPE; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

BACTERIAL VACCINES; DRUG COMPOUNDING; DRUG DESIGN; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 84893492487     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201014666131226125540     Document Type: Review

References (49)

1. Cunningham, M. W. Pathogenesis of group A streptococcal infections and their sequelae. Adv. Experiment. Med. Biol., 2008, 609, 29-42.
2. Carapetis, J. R.; Steer, A. C.; Mulholland, E. K.; Weber, M. The global burden of group A streptococcal diseases. Lancet Infect. Dis., 2005, 5(11), 685-694.
3. Henningham, A.; Gillen, C. M.; Walker, M. J. Group a streptococcal vaccine candidates: potential for the development of a human vaccine. Curr. Topics Microbiol. Immunol., 2013, 368, 207-242.
4. Dale, J. B.; Fischetti, V. A.; Carapetis, J. R.; Steer, A. C.; Sow, S.; Kumar, R.; Mayosi, B. M.; Rubin, F. A.; Mulholland, K.; Hombach, J. M.; Schödel, F.; Henao-Restrepo, A. M. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine, 2013, 31(Suppl 2), B216-222.
5. Thomas, C. L.; Lee, S. W. Knowing is half the battle: targeting virulence factors of group A Streptococcus for vaccine and therapeutics. Curr. Drug Targets, 2012, 13(3), 308-322.
6. Bronze, M. S.; Courtney, H. S.; Dale, J. B. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J. Immun., 1992, 148(3), 888-893.
7. Smeesters, P. R.; Mardulyn, P.; Vergison, A.; Leplae, R.; Van Melderen, L. Genetic diversity of group A streptococcus M protein: implications for typing and vaccine development. Vaccine, 2008, 26(46), 5835-5842.
8. Cunningham, M. W. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front. Biosci., 2003, 8, s533-543.
9. Dale, J. B.; Penfound, T.; Chiang, E. Y.; Long, V.; Shulman, S. T.; Beall, B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin. Diagnost. Lab. Immunol., 2005, 12(7), 833-836.
10. Dale, J. B.; Chiang, E. Y.; Lederer, J. W. Recombinant tetravalent group A streptococcal M protein vaccine. J. Immun., 1993, 151(4), 2188-2194.
11. Dale, J. B. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine, 1999, 17(2), 193-200.
12. Dale, J. B.; Simmons, M.; Chiang, E. C.; Chiang, E. Y. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine, 1996, 14(10), 944-948.
13. Hu, M. C.; Walls, M. A.; Stroop, S. D.; Reddish, M. A.; Beall, B.; Dale, J. B. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect. Immun., 2002, 70(4), 2171-2177.
14. McNeil, S.; Halperin, S.; Langley, J. M.; Smith, B.; Baxendale, D. M.; Warren, A.; Sharratt, G. P.; Baxendale, D. M.; Reddish, M. A.; Hu, M. C.; Stroop, S. D.; Linden, J.; Fries, L. F.; Vink, P. E.; Dale, J. B. A double-blind, randomized, phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. Int. Congr. Series, 2006, 1289, 303-306.
15. McNeil, S. A.; Halperin, S. A.; Langley, J. M.; Smith, B.; Warren, A.; Sharratt, G. P.; Baxendale, D. M.; Reddish, M. A.; Hu, M. C.; Stroop, S. D.; Linden, J.; Fries, L. F.; Vink, P. E.; Dale, J. B. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis., 2005, 41(8), 1114-1122.
16. Dale, J. B.; Penfound, T. A.; Chiang, E. Y.; Walton, W. J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine, 2011, 29 (46), 8175-8178.
17. Brandt, E. R.; Hayman, W. A.; Currie, B.; Carapetis, J.; Wood, Y.; Jackson, D. C.; Cooper, J.; Melrose, W. D.; Saul, A. J.; Good, M. F. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology, 1996, 89(3), 331-337.
18. Hayman, W. A.; Brandt, E. R.; Relf, W. A; Cooper, J.; Saul, A.; Good, M. F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int. Immun., 1997, 9(11), 1723-1733.
19. Penfound, T.; Chiang, E.; Ahmed, E.; Dale, J. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine, 2010, 28 (31), 5017-5022.
20. Ji, Y.; McLandsborough, L.; Kondagunta, A.; Cleary, P. P. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect. Immun., 1996, 64(2), 503-510.
21. Park, H. S.; Cleary, P. P. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect. Immun., 2005, 73(12), 7878-7886.
22. Cleary, P. P.; Matsuka, Y. V.; Huynh, T.; Lam, H.; Olmsted, S. B. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine, 2004, 22(31-32), 4332-4341.
23. Kurupati, P.; Turner, C. E.; Tziona, I.; Lawrenson, R. A.; Alam, F. M.; Nohadani, M.; Stamp, G. W.; Zinkernagel, A. S.; Nizet, V.; Edwards, R. J.; Sriskandan, S. Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. Molecul. Microbiol., 2010, 76 (6), 1387-1397.
24. Turner, C. E.; Kurupati, P.; Wiles, S.; Edwards, R. J.; Sriskandan, S. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine, 2009, 27(36), 4923-4929.
25. Mora, M.; Bensi, G.; Capo, S.; Falugi, F.; Zingaretti, C.; Manetti, A. G.; Maggi. T.; Taddei. A. R.; Grandi, G.; Telford, J, L. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc. Nat. Acad. Sci. USA, 2005, 102(43), 15641-15646.
26. McArthur, J.; Medina, E.; Mueller, A.; Chin, J.; Currie, B. J.; Sriprakash, K. S.; Talay, S. R.; Chhatwal, G. S.; Walker, M. J. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect. Immun., 2004, 72(12), 7342-7345.
27. Zhu, H.; Liu, M.; Lei, B. The surface protein Shr of Streptococcus pyogenes binds heme and transfers it to the streptococcal hemebinding protein Shp. BMC Microbiol., 2008, 8, 15.
28. Lu, C.; Xie, G.; Liu, M.; Zhu, H.; Lei, B. Direct heme transfer reactions in the group A streptococcus heme acquisition pathway. PLoS One, 2012, 7(5), e37556.
29. Huang, Y. S.; Fisher, M.; Nasrawi, Z.; Eichenbaum, Z. Defense from the group a streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor. J. Infect. Dis., 2011, 203(11), 1595-1601.
30. Sabharwal, H.; Michon, F.; Nelson, D.; Dong, W.; Fuchs, K.; Manjarrez, R. C.; Sarkar, A.; Uitz, C.; Viteri-Jackson, A.; Suarez, R. S.; Blake, M.; Zabriskie, J. B. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J. Infect. Dis., 2006, 193(1), 129-135.
31. Chmouryguina, I.; Suvorov, A.; Ferrieri, P.; Cleary, P. P. Conservation of the C5a peptidase genes in group A and B streptococci. Infect. Immun., 1996, 64(7), 2387-2390.
32. Sumby, P.; Zhang, S.; Whitney, A. R.; Falugi, F.; Grandi, G.; Graviss, E. A.; Deleo, F. R.; Musser, J. M. A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response. Infect. Immun., 2008, 76(3), 978-985.
33. Talay, S. R.; Valentin-Weigand, P.; Timmis, K. N.; Chhatwal, G. S. Domain structure and conserved epitopes of Sfb protein, the fibronectin-binding adhesin of Streptococcus pyogenes. Mol. Microbiol., 1994, 13(3), 531-539.
34. Henningham, A.; Chiarot, E.; Gillen, C. M.; Cole, J. N.; Rohde, M.; Fulde, M.; Ramachandran, V.; Cork, A. J.; Hartas, J.; Magor, G.; Djordjevic, S. P.; Cordwell, S. J.; Kobe, B.; Sriprakash, K. S.; Nizet, V.; Chhatwal, G. S.; Margarit Immaculada, Y. R.; Batzloff, M. R.; Walker, M. J. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J. Molecul. Med., 2012, 90(10), 1197-1207.
35. Henningham, A.; Ericsson, D. J.; Langer, K.; Casey, L. W.; Jovcevski, B.; Chhatwal, G. S.; Aquilina, J. A.; Batzloff, M. R.; Kobe, B.; Walker, M. J. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus. MBio, 2013, 4(4), e00509-513.
36. Bensi, G.; Mora, M.; Tuscano, G.; Biagini, M.; Chiarot, E.; Bombaci, M.; Capo, S.; Falugi, F.; Manetti, A. G.; Donato, P.; Swennen, E.; Gallotta, M.; Garibaldi, M.; Pinto, V.; Chiappini, N.; Musser, J. M.; Janulczyk, R.; Mariani, M.; Scarselli, M.; Telford, J. L.; Grifantini, R.; Norais, N.; Margarit, I.; Grandi, G. Multi highthroughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Molecul. Cellul. Proteomics, 2012, 11(6), M111. 015693.
37. Ma, C. Q.; Li, C. H.; Wang, X. R.; Zeng, R. H.; Yin, X. L.; Feng, H. D.; Wei, L. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice. Cell. Mol. Immun., 2009, 6(1), 73-77.
38. Okamoto, S.; Tamura, Y.; Terao, Y.; Hamada, S.; Kawabata, S. Systemic immunization with streptococcal immunoglobulinbinding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice. Vaccine, 2005, 23(40), 4852-4859.
39. Roggiani, M.; Stoehr, J. A.; Olmsted, S. B.; Matsuka, Y. V.; Pillai, S.; Ohlendorf, D. H.; Schlievert, P. M. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect. Immun., 2000, 68(9), 5011-5017.
40. McCormick, J. K.; Tripp, T. J.; Olmsted, S. B.; Matsuka, Y. V.; Gahr, P. J.; Ohlendorf, D. H.; Schlievert, P. M. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that is protective in the rabbit model of toxic shock syndrome. J. Immun., 2000, 165(4), 2306-2312.
41. Engleberg, N. C.; Heath, A.; Vardaman, K.; DiRita, V. J. Contribution of CsrR-regulated virulence factors to the progress and outcome of murine skin infections by Streptococcus pyogenes. Infect. Immun., 2004, 72(2), 623-628.
42. Kapur, V.; Maffei, J. T.; Greer, R. S.; Li, L. L.; Adams, G. J.; Musser, J. M. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb. Pathogen., 1994, 16 (6), 443-450.
43. Kappeler, K. V.; Anbalagan, S.; Dmitriev, A. V.; McDowell, E. J.; Neely, M. N.; Chaussee, M. S. A naturally occurring Rgg variant in serotype M3 Streptococcus pyogenes does not activate speB expression due to altered specificity of DNA binding. Infect. Immun., 2009, 77(12), 5411-5417.
44. Olsen, R. J.; Laucirica, D. R.; Watkins, M. E.; Feske, M. L.; Garcia-Bustillos, J. R.; Vu, C.; Cantu, C.; Shelburne, S. A 3rd.; Fittipaldi, N.; Kumaraswami, M.; Shea, P. R.; Flores, A. R.; Beres, S. B.; Lovgren, M.; Tyrrell, G. J.; Efstratiou, A.; Low, D. E.; Van Beneden, C. A.; Musser, J. M. Polymorphisms in regulator of protease B (RopB) alter disease phenotype and strain virulence of serotype M3 group A Streptococcus. J. Infect. Dis., 2012, 205(11), 1719-1729.
45. Liu, M.; Zhu, H.; Zhang, J.; Lei, B. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect. Immun., 2007, 75(7), 3651-3657.
46. Zhu, H.; Liu, M.; Sumby, P.; Lei, B. The secreted esterase of group a streptococcus is important for invasive skin infection and dissemination in mice. Infect. Immun., 2009, 77(12), 5225-5232.
47. Liu, M.; Zhu, H.; Li, J.; Garcia, C. C.; Feng, W.; Kirpotina, L. N.; Hilmer, J.; Tavares, L. P.; Layton, A. W.; Quinn, M. T.; Bothner, B,; Teixeira, M. M.; Lei, B. group a streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion. PLoS Pathogens, 2012, 8(4): e1002624.
48. Li, J.; Zhu, H.; Feng, W.; Liu, M.; Song, Y.; Zhang, X.; Zhou, Y.; Bei, W.; Lei, B. Regulation of inhibition of neutrophil infiltration by the two-component regulatory system CovRS in subcutaneous murine infection with group A streptococcus. Infect. Immun., 2013, 81(3), 974-983.
49. Liu, G.; Liu, M.; Xie, G.; Lei, B. Characterization of streptococcal platelet-activating factor acetylhydrolase variants that are involved in innate immune evasion. Infect. Immun., 2013, 81(9), 3128-3138.